Notably, phase I clinical trials in patients with diabetic kidney disease (DKD) [210] and idiopathic pulmonary fibrosis (IPF) [211] demonstrated that the combination of dasatinib and quercetin (D+Q) reduces the expression of p16INK4A and senescence-associated β-galactosidase (SA-β-gal), hallmarks of senescence that signify irreversible cell cycle arrest and ageing-related dysfunction. The gene discussed is CDKN2A; the disease is idiopathic pulmonary fibrosis.